News >

Japanese Approval Sought for Frontline Osimertinib in NSCLC

Jason M. Broderick @jasoncology
Published: Monday, Nov 27, 2017

lung cancer
A supplemental new drug application (sNDA) has been submitted to Japan’s Pharmaceuticals and Medical Devices Agency for the use of osimertinib (Tagrisso) as a frontline treatment for patients with inoperable or recurrent EGFR-positive non–small cell lung cancer (NSCLC).

Overall, 33.7% of patients experienced a grade ≥3 AE in the osimertinib group compared with 44.8% for erlotinib and gefitinib. Patients in the osimertinib group were less like to discontinue treatment because of AEs (13.3% vs 18.1%).
Ramalingam S, Reungwetwattana T, Chewaskulyong B, et al. Osimertinib vs standard of care (SoC) EGFR-TKI as first-line therapy in patients (pts) with EGFRm advanced NSCLC: FLAURA. Presented at: 2017 ESMO Congress; Madrid, Spain; September 9-12, 2017. Abstract LBA2_PR.

... to read the full story
To Read the Full Story

View Conference Coverage
Online CME Activities
TitleExpiration DateCME Credits
Advances in™ Therapies for Patients With ALK-Positive Lung Cancers: More Options…More Decisions…Better OutcomesAug 30, 20191.5
Oncology Briefings™: Treating Advanced NSCLC Without Actionable MutationsAug 30, 20191.0
Publication Bottom Border
Border Publication
x